Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2013 2
2014 1
2016 2
2017 3
2018 2
2019 3
2020 7
2021 5
2022 6
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.
Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V, Carnovale V. Castaldo A, et al. Among authors: iacotucci p. Front Mol Biosci. 2024 Jan 8;10:1327958. doi: 10.3389/fmolb.2023.1327958. eCollection 2023. Front Mol Biosci. 2024. PMID: 38259684 Free PMC article.
Lipidomic alterations in human saliva from cystic fibrosis patients.
Caterino M, Fedele R, Carnovale V, Castaldo A, Gelzo M, Iacotucci P, Ruoppolo M, Castaldo G. Caterino M, et al. Among authors: iacotucci p. Sci Rep. 2023 Jan 12;13(1):600. doi: 10.1038/s41598-022-24429-6. Sci Rep. 2023. PMID: 36635275 Free PMC article.
Clinical outcomes of digital health in adults with cystic fibrosis.
Carnovale V, Iacotucci P, Qiao D, Ferrillo L, Somma J, Buonaurio S, Marcella d'Ippolito, Celardo A, Savi D. Carnovale V, et al. Among authors: iacotucci p. Respir Med. 2022 Oct;202:106970. doi: 10.1016/j.rmed.2022.106970. Epub 2022 Aug 28. Respir Med. 2022. PMID: 36058164
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype.
Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N, Majo F, Ciciriello F, Padoan R, Poli P, Taccetti G, Centrone C, Casciaro R, Castellani C, Salvatore D, Colangelo C, Bonomi P, Castaldo G, Terlizzi V. Tosco A, et al. Among authors: iacotucci p. J Cyst Fibros. 2022 Sep;21(5):850-855. doi: 10.1016/j.jcf.2022.04.020. Epub 2022 May 4. J Cyst Fibros. 2022. PMID: 35523714
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, Francalanci M, Taccetti G, Buonaurio S, Celardo A, Salvadori L, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D. Carnovale V, et al. Among authors: iacotucci p. J Clin Med. 2022 Feb 16;11(4):1021. doi: 10.3390/jcm11041021. J Clin Med. 2022. PMID: 35207295 Free PMC article.
Employment Status and Work Ability in Adults with Cystic Fibrosis.
Leso V, Carnovale V, Iacotucci P, Pacella D, Romano R, Della Volpe I, Iavicoli I. Leso V, et al. Among authors: iacotucci p. Int J Environ Res Public Health. 2021 Nov 10;18(22):11776. doi: 10.3390/ijerph182211776. Int J Environ Res Public Health. 2021. PMID: 34831532 Free PMC article.
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Medio P, Ferrillo L, De Gregorio F, Francalanci M, Taccetti G, Buonaurio S, d'Ippolito M, Marsicovetere G, D'Andria M, Ferrara N, Salvatore D. Carnovale V, et al. Among authors: iacotucci p. Respir Med. 2021 Nov-Dec;189:106646. doi: 10.1016/j.rmed.2021.106646. Epub 2021 Oct 12. Respir Med. 2021. PMID: 34673344 Free article.
33 results